Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Robert Bradway, chairman and CEO said, “Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

The $52-per-share offer would give Amgen a drug that some analysts have described as a pipeline in a pill with $1 billion-plus sales potential, and is a sizeable premium on ChemoCentryx' pre-deal ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

However, if this ban was upheld, it could hurt the industry. Another risk to Amgen is the potential that the drugs in its pipeline may not commercially materialize as expected. That could ...

Analysts note that while the base business remains resilient, the focus has shifted to Amgen's pipeline and potential growth drivers. The integration of the Horizon franchise, bolstered by Tepezza ...

Analysts note that while the base business remains resilient, the focus has shifted to Amgen's pipeline and potential growth drivers. The integration of the Horizon franchise, bolstered by Tepezza's ...